These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26785814)

  • 41. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions.
    Tomasetti C; Vogelstein B
    Science; 2015 Jan; 347(6217):78-81. PubMed ID: 25554788
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tissue-specificity in cancer: The rule, not the exception.
    Haigis KM; Cichowski K; Elledge SJ
    Science; 2019 Mar; 363(6432):1150-1151. PubMed ID: 30872507
    [No Abstract]   [Full Text] [Related]  

  • 43. Mutation and tissue lineage lead to organ-specific cancer.
    Arner EN; Rathmell WK
    Nature; 2022 Jun; 606(7916):871-872. PubMed ID: 35676353
    [No Abstract]   [Full Text] [Related]  

  • 44. Somatic mutation accumulation seen through a single-molecule lens.
    Luquette LJ; Park PJ
    Cell Res; 2021 Sep; 31(9):949-950. PubMed ID: 34316001
    [No Abstract]   [Full Text] [Related]  

  • 45. How many mutations are required for tumorigenesis? Implications from human cancer data.
    Renan MJ
    Mol Carcinog; 1993; 7(3):139-46. PubMed ID: 8489711
    [No Abstract]   [Full Text] [Related]  

  • 46. Relaxed selection and mutation accumulation are best studied empirically: reply to Woodley of Menie
    Arslan RC; Willführ KP; Frans EM; Verweij KJH; Bürkner PC; Myrskylä M; Voland E; Almqvist C; Zietsch BP; Penke L
    Proc Biol Sci; 2018 Feb; 285(1873):. PubMed ID: 29467268
    [No Abstract]   [Full Text] [Related]  

  • 47. A method for determining mutation rate and tumor incidence simultaneously.
    BURDETTE WJ
    Cancer Res; 1951 Jul; 11(7):552-4. PubMed ID: 14848827
    [No Abstract]   [Full Text] [Related]  

  • 48. Redistribution of mutation risk in cancer.
    Hu X; De S
    Nat Cancer; 2024 Feb; 5(2):216-217. PubMed ID: 38418776
    [No Abstract]   [Full Text] [Related]  

  • 49. Contributions of the Intrinsic Mutation Process to Cancer Mutation and Risk Burdens.
    Zhu W; Wu S; Hannun YA
    EBioMedicine; 2017 Oct; 24():5-6. PubMed ID: 28958657
    [No Abstract]   [Full Text] [Related]  

  • 50. Mutation load under additive fitness effects.
    Bergen AC
    Genet Res (Camb); 2015 Feb; 97():e2. PubMed ID: 26788801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of recessive effect of human polymerase δ proofreading deficiency through mutational analysis of POLD1-mutated normal and cancer cells.
    Andrianova MA; Seplyarskiy VB; Terradas M; Sánchez-Heras AB; Mur P; Soto JL; Aiza G; Borràs E; Kondrashov FA; Kondrashov AS; Bazykin GA; Valle L
    Eur J Hum Genet; 2024 Jul; 32(7):837-845. PubMed ID: 38658779
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma.
    Tümen D; Heumann P; Gülow K; Demirci CN; Cosma LS; Müller M; Kandulski A
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551958
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Game of clones: Battles in the field of carcinogenesis.
    Rahal Z; Sinjab A; Wistuba II; Kadara H
    Pharmacol Ther; 2022 Sep; 237():108251. PubMed ID: 35850404
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors.
    Vesely C; Wong YNS; Childs A; Akarca AU; Dhami P; Vaikkinen H; Conde L; Herrero J; Ogunbiyi O; Gander A; Luong TV; Thirlwell C; Caplin M; Toumpanakis C; Peggs K; Quezada SA; Marafioti T; Meyer T
    Clin Cancer Res; 2022 Jun; 28(12):2657-2668. PubMed ID: 35320356
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Similar burden of pathogenic coding variants in exceptionally long-lived individuals and individuals without exceptional longevity.
    Gutman D; Lidzbarsky G; Milman S; Gao T; Sin-Chan P; Gonzaga-Jauregui C; ; Deelen J; Shuldiner AR; Barzilai N; Atzmon G
    Aging Cell; 2020 Oct; 19(10):e13216. PubMed ID: 32860726
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inference of clonal selection in cancer populations using single-cell sequencing data.
    Skums P; Tsyvina V; Zelikovsky A
    Bioinformatics; 2019 Jul; 35(14):i398-i407. PubMed ID: 31510696
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Network of Cancer Genes (NCG): a comprehensive catalogue of known and candidate cancer genes from cancer sequencing screens.
    Repana D; Nulsen J; Dressler L; Bortolomeazzi M; Venkata SK; Tourna A; Yakovleva A; Palmieri T; Ciccarelli FD
    Genome Biol; 2019 Jan; 20(1):1. PubMed ID: 30606230
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cancer progression models and fitness landscapes: a many-to-many relationship.
    Diaz-Uriarte R
    Bioinformatics; 2018 Mar; 34(5):836-844. PubMed ID: 29048486
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Distinct mutation accumulation rates among tissues determine the variation in cancer risk.
    Hao D; Wang L; Di LJ
    Sci Rep; 2016 Jan; 6():19458. PubMed ID: 26785814
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exploring the implications of distinct mutational signatures and mutation rates in aging and cancer.
    Fox EJ; Salk JJ; Loeb LA
    Genome Med; 2016 Mar; 8(1):30. PubMed ID: 26987311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.